Increased AURKA Gene Copy Number Correlates with Poor Prognosis and Predicts the Efficacy of High-dose Interferon Therapy in Acral Melanoma.
Increased AURKA Gene Copy Number Correlates with Poor Prognosis and Predicts the Efficacy of High-dose Interferon Therapy in Acral Melanoma.
复制标题
AURKA 基因拷贝数增加与预后不良相关，并预测高剂量干扰素治疗肢端黑色素瘤的疗效
DOI：
10.7150/jca.24013
复制
发表时间：
2018
影响因子：
3.9
通讯作者：
Guo J
中科院分区：
文献类型：
--
作者：
Yan J;Yu J;Wu X;Xu T;Yu H;Dai J;Ma M;Tang H;Xu L;Chi Z;Si L;Sheng X;Cui C;Kong Y;Guo J
背景：AURKA 激酶是有丝分裂和染色体稳定性所必需的丝氨酸/苏氨酸激酶。 AURKA 的异常扩增和过度表达常见于各种类型的癌症，包括皮肤黑色素瘤。然而，AURKA拷贝数（CN）在肢端黑色素瘤（AM）中的地位和临床意义尚未完全阐明。方法：本研究纳入了 472 个 AM 样本。使用 QuantiGenePlex DNA 检测对 AURKA CN 进行了检查。我们分析了 AURKA CN 与 AM 患者的临床病理特征和生存率的关系。结果：在本研究中，24.6%（116/472）的样本中检测到 AURKA 拷贝增益（设置为超过 2.0 拷贝）。我们没有观察到患者的临床病理特征与 AURKA 拷贝增益之间存在任何明显的相关性。然而，AURKA拷贝增益患者的总生存时间（OS）和无进展生存时间（PFS）显着短于AURKA CN正常的患者（OS：P = 0.022；PFS：P < 0.001）。此外，多变量 Cox 回归分析显示，AURKA 拷贝增益是接受干扰素辅助治疗的 AM 患者的独立不良预后因素。结论：本研究表明 AURKA 拷贝增益是 AM 的不良预后因素。此外，AURKA 拷贝增益可能是预测 AM 患者干扰素治疗结果的有用生物标志物。
Background: AURKA kinase is an essential serine/threonine kinase for mitosis and chromosome stability. The aberrant amplification and overexpression of AURKA are commonly observed in various types of cancer, including cutaneous melanoma. However, the status and the clinical significance of AURKA copy number (CN) in acral melanoma (AM) have not been fully elucidated. Methods: Four hundred and seventy-two AM samples were included in the study. AURKA CN was examined using the QuantiGenePlex DNA Assay. We analysed the relationship of AURKA CN to clinicopathological characteristics and survival of patients with AM. Results: In this study, AURKA copy gain (set as more than 2.0 copies) was detected in 24.6% (116/472) of the samples. We did not observe any obvious correlation between clinicopathological characteristics and AURKA copy gain of the patients. However, patients with AURKA copy gain had a significantly shorter overall survival time (OS) and progression-free survival time (PFS) than those with normal AURKA CN (OS: P = 0.022; PFS: P < 0.001). Furthermore, multivariate Cox regression analysis showed that AURKA copy gain was an independent poor prognostic factor for patients with AM undergoing adjuvant interferon therapy. Conclusions: This study suggested that AURKA copy gain is an adverse prognostic factor for AM. Furthermore, AURKA copy gain may be a useful biomarker to predict the outcome of interferon therapy in patients with AM.
登录
查看更多内容
DOI：
10.1056/nejmoa1003466
发表时间：
2010-08-19
期刊：
The New England journal of medicine
影响因子：
--
作者：
Hodi FS;O'Day SJ;McDermott DF;Weber RW;Sosman JA;Haanen JB;Gonzalez R;Robert C;Schadendorf D;Hassel JC;Akerley W;van den Eertwegh AJ;Lutzky J;Lorigan P;Vaubel JM;Linette GP;Hogg D;Ottensmeier CH;Lebbé C;Peschel C;Quirt I;Clark JI;Wolchok JD;Weber JS;Tian J;Yellin MJ;Nichol GM;Hoos A;Urba WJ
通讯作者：
Urba WJ
中国黑色素瘤患者 KIT 畸变的大规模分析
影响因子：
11.5
作者：
Kong, Yan;Si, Lu;Guo, Jun
通讯作者：
Guo, Jun
影响因子：
158.5
作者：
Robert, Caroline;Schachter, Jacob;Ribas, Antoni
通讯作者：
Ribas, Antoni
影响因子：
50.5
作者：
Schoffski, P.;Besse, B.;Delord, J. -P.
通讯作者：
Delord, J. -P.
影响因子：
2.4
作者：
Rex, Jordi;Paradelo, Cristina;Ferrandiz, Carlos
通讯作者：
Ferrandiz, Carlos